Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
OpenAlex 토픽 ·
Prostate Cancer Treatment and Research
Prostate Cancer Diagnosis and Treatment
Radiopharmaceutical Chemistry and Applications
APA
K. Fizazi, G. Attard, et al. (2026). Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.. Annals of oncology : official journal of the European Society for Medical Oncology, 37(5), 590-607. https://doi.org/10.1016/j.annonc.2026.01.015
MLA
K. Fizazi, et al.. "Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.." Annals of oncology : official journal of the European Society for Medical Oncology, vol. 37, no. 5, 2026, pp. 590-607.
PMID
41679466
같은 제1저자의 인용 많은 논문 (5)
- Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
- Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
- Health-related quality of life, pain, and symptomatic skeletal events with [Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.
- Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.